HRTS — Tema Heart & Health ETF

Is HRTS overbought or oversold? Here is the current MarketMoodz read.

ETF

Neutral As of August 19, 2026

Tema Heart & Health ETF (HRTS) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The ETF name last closed at $37.83. The rating moved from Overbought to Neutral on August 18, 2026.

AI analysis

Tema Heart & Health ETF (HRTS) offers targeted exposure to cardiovascular and related healthcare equities, benefiting from secular demand drivers and defensive sector attributes. Absent clear public filing detail or strong social/research signals, near-term performance is likely to track thematic flows and broader market sentiment; liquidity and concentration in underlying holdings are primary operational risks. Short-term catalysts are ETF flows tied to macro headlines and healthcare-specific news (clinical outcomes, regulatory decisions). Overall outlook is neutral-to-cautiously constructive over the medium term, with downside susceptibility to rapid fund outflows or negative clinical/regulatory events.

Key factors

  • Thematic exposure to cardiovascular and broader health-care related names benefits from secular demographic tailwinds (aging populations, chronic disease prevalence).
  • Healthcare sector historically offers defensive characteristics in risk-off environments, which can stabilize flows during market stress.
  • ETF wrapper provides diversified exposure across devices, biotech, pharma and services tied to heart & health themes, limiting single-stock idiosyncratic risk relative to individual equities.
  • Current market backdrop is cautiously optimistic with rotation dynamics; ETF flows may be headline-driven and sensitive to macro shifts rather than fundamentals.
  • Limited public filings / social sentiment data available increases uncertainty about underlying holdings, expense ratio and AUM trends that drive liquidity and tracking performance.

Risks

  • Concentration risk if the ETF holds a small number of large positions or is heavily weighted to biotech/device names with binary clinical/regulatory outcomes.
  • Liquidity and AUM risk for a niche thematic ETF: low flows can magnify spreads, tracking error, and make rapid rebalancing costly.
  • Regulatory and reimbursement risk in health-care policy changes can materially affect constituent revenues and valuation multiples.
  • Macro-driven ETF volatility and crowded positioning (low options IV vs realized vol) increases chance of sharp outflows and short-term price dislocations.
  • Limited transparency in available data (no EDGAR/filings or social/research signals provided) increases model and forecasting uncertainty.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for HRTS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.